All GLG News Analyses Filed Under: Endocrinology

1. Infectobesity, or obesity resulting from infection, is reproducible in mice, and implied in people.2. This is most likely not a fad: there is serious money, and serious research, and it is scientifically logical3. If there was one diet that worked, we would all be on it: the cause of weight gain...

*Weight loss must be taken into account in agent selection*90 percent of type II patients are overweight...not so type I*The epidemic of diabetes is nearly all type II patients, and most do not require insulin, and should not.

Inhaled insulin is a novel mode of delivery. True no needles, but a bulky, somewhat cumbersome device that may need a very smart and diligent individual to be able to figure out the right dose to give.  How well it will be accepted by patients will be the key.

The indications for hormone therapy in younger postmenopausal women is still mainly symptom relief of hot flashes etc. Side effects still remain, and prevention of cardiovascular disease, dementia and depression are not there. It may help with osteoporosis, but we have better drugs. The diabetes data...

*Investor and management ownership/recent sales of NTRI, up 2461 percent in 2 years.*Little (needed) detail of actual operations, dietary content*Marketing weight loss as a strategy for long term success

The article cites guidelines from North American Menopause Soc. which does review the risks and benefits of hormone replacement.  However, these guidelines do emphasize carefully treating those women in early menopause with hormones, assuming they are not high risk patients for breast cancer. The...

Article starts with short patient "vignette," illustrating a typical patient who would be suitable for this new insulin delivery system. The article contrasts inhaled insulin with other forms of insulin (injectible, short and long acting), has excellent illustration of inhalation device, reviews pros...

1. There are no new drugs designed to raise HDL anywhere close to coming to market2. Niacin remains the best agent on the market (in terms of HDL raising and improved outcomes) and is undergoing some potential improvement to reduce annoying side effects3. There remains great debate as to what the biological...

The surrogate atherosclerosis end point studies with torcetrapib promise to give important, but likely complex clues regarding its paradoxical increase in CVD events and mortality. Some promising HDL-raising approaches still appear to be eluding pharmaceutical R&D.Niacin promises to be a big winner...

The addition of zetia to any statin will increase efficacy for LDL lowering by an average of 18%. This clearly is advantageous where one wants the LDL to be below 100, or even below 70. In view of the relative efficacy of the individual components, the result comes as no surprise. However, with...